Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.32 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20070278 | 0.79 | RET (0.51) | RETCYP2C19 | |
| SCHEMBL9937728 | 0.78 | CTSK (0.37) | NR1H2EPHX2ACKR3F2RL1 | |
| SCHEMBL22118141 | 0.76 | CTSK (0.36) | NR1H2ACKR3F2RL1 | |
| SCHEMBL20205793 | 0.76 | RET (0.50) | RET | |
| SCHEMBL20148022 | 0.76 | RET (0.50) | RETNR1H2 | |
| SCHEMBL21150506 | 0.75 | CTSK (0.39) | RETNR1H2EPHX2F2RL1 | |
| SCHEMBL29939292 | 0.70 | CTSK (0.35) | NR1H2F2RL1 | |
| SCHEMBL20069544 | 0.70 | CTSK (0.33) | RETNR1H2 | |
| SCHEMBL24421280 | 0.70 | USP2 (0.46) | NR1H2GPR119EPHX2F2RL1 | |
| SCHEMBL22862954 | 0.70 | USP2 (0.39) | NR1H2GPR119EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-12-10 | — | — | US | disclosed |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RET 1/4885NR1H2 3440/4885GPR119 1905/4885 |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RET 1/4885NR1H2 3440/4885GPR119 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.